Papillomavirus Infections

• 

  Subject Areas on Research

  • 'I'm here to save my life': a qualitative study of experiences navigating a cryotherapy referral system for human papillomavirus-positive women in western Kenya. 
  • A 40-year-old man with a perforated cheek. 
  • A Comparison of Parent- and Provider-Reported Human Papillomavirus Vaccination of Adolescents. 
  • A Pilot Study of a Screening Program for Human Papillomavirus-Related Squamous Intraepithelial Lesion and Malignancy in Gynecologic Oncology Patients. 
  • A Qualitative Exploration of Barriers to Treatment Among HPV-Positive Women in a Cervical Cancer Screening Study in Western Kenya. 
  • A Qualitative Exploration of Women's Experiences with a Community Health Volunteer-Led Cervical Cancer Educational Module in Migori County, Kenya. 
  • A Review and Update on Papillary Immature Metaplasia of the Uterine Cervix: A Distinct Subset of Low-Grade Squamous Intraepithelial Lesion, Proposing a Possible Cell of Origin. 
  • A TGF-β1 genetic variant at the miRNA187 binding site significantly modifies risk of HPV16-associated oropharyngeal cancer. 
  • A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. 
  • A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer. 
  • A functional variant at miRNA-122 binding site in IL-1α 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer. 
  • A functional variant at the miRNA binding site in E2F1 gene is associated with risk and tumor HPV16 status of oropharynx squamous cell carcinoma. 
  • A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer. 
  • A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. 
  • A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. 
  • A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. 
  • A pilot study of Helicobacter pylori infection and risk of laryngopharyngeal cancer. 
  • A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. 
  • A public health approach to cervical cancer screening in Africa through community-based self-administered HPV testing and mobile treatment provision. 
  • A systematic review of human papillomavirus vaccination among US adolescents. 
  • A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. 
  • ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. 
  • Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. 
  • Achieving equity in cervical cancer screening in low- and middle-income countries (LMICs): Strengthening health systems using a systems thinking approach. 
  • Age-specific occurrence of HPV16- and HPV18-related cervical cancer. 
  • American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. 
  • American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. 
  • American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. 
  • Anal cancer: an overview. 
  • Anal human papillomavirus and HIV: A cross-sectional study among men who have sex with men in Moscow, Russia, 2012-2013. 
  • Anal-rectal cytology: correlation with human papillomavirus status and biopsy diagnoses in a population of HIV-positive patients. 
  • Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. 
  • Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. 
  • Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. 
  • Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine. 
  • Assessing university students' sexual risk behaviors as predictors of human papillomavirus (HPV) vaccine uptake behavior. 
  • Association Between Parental HPV Knowledge and Intentions to Have Their Daughters Vaccinated. 
  • Association of Human Papillomavirus Status With Suicide Risk Among Patients With Head and Neck Cancer. 
  • Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer. 
  • Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. 
  • Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non-Hispanic whites. 
  • Association of tumor necrosis factor-alpha promoter variants with risk of HPV-associated oral squamous cell carcinoma. 
  • Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. 
  • Associations of health behaviors with human papillomavirus vaccine uptake, completion, and intentions among female undergraduate students. 
  • Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. 
  • Barriers and Facilitators to Cervical Cancer Screening in Western Kenya: a Qualitative Study. 
  • Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay. 
  • CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. 
  • Can portable Colposcopes Replace Standard-of-care Colposcopes? A Crossover Trial of Two Portable Colposcopes with a Standard-of-Care Video Colposcope. 
  • Cervical Cancer Screening. 
  • Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Cervical Cancer-Related Knowledge, Attitudes, Practices and Self-Screening Acceptance Among Patients, Employees, and Social Media Followers of Major Brazilian Hospital. 
  • Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. 
  • Cervical cancer screening through human papillomavirus testing in community health campaigns versus health facilities in rural western Kenya. 
  • Chapter 19: Cost-effectiveness of cervical cancer screening. 
  • Characterization of gut-derived intraepithelial lymphocyte (IEL) residing in human papillomavirus (HPV)-infected intraepithelial neoplastic lesions. 
  • Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. 
  • Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. 
  • Coincidence analysis: a new method for causal inference in implementation science. 
  • Combined p53-related genetic variants together with HPV infection increase oral cancer risk. 
  • Comparison of patient flow and provider efficiency of two delivery strategies for HPV-based cervical cancer screening in Western Kenya: a time and motion study. 
  • Comparison of the costs of HPV testing through community health campaigns versus home-based testing in rural Western Kenya: a microcosting study. 
  • Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. 
  • Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States. 
  • Cost-effectiveness of a potential vaccine for human papillomavirus. 
  • Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. 
  • Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. 
  • Developing a framework to describe stigma related to cervical cancer and HPV in western Kenya. 
  • Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. 
  • Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. 
  • Differences in Sociodemographic Correlates of Human Papillomavirus-Associated Cancer Survival in the United States. 
  • Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. 
  • Differences in imaging characteristics of HPV-positive and HPV-Negative oropharyngeal cancers: a blinded matched-pair analysis. 
  • Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. 
  • Different strokes for different folks: new paradigms for staging oropharynx cancer. 
  • Disparities in Provider Recommendation of Human Papillomavirus Vaccination for U.S. Adolescents. 
  • Disparities in healthcare access and utilization and human papillomavirus (HPV) vaccine initiation in the United States. 
  • Disparities in human papillomavirus (HPV) vaccine initiation and completion based on sexual orientation among women in the United States. 
  • Does Self-Efficacy Mediate the Relationships Between Social-Cognitive Factors and Intentions to Receive HPV Vaccination Among Young Women? 
  • Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer. 
  • Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. 
  • E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. 
  • Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. 
  • Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women. 
  • Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. 
  • Effects of a randomized controlled trial of a brief, student-nurse led, parent-based sexual health intervention on parental protective factors and HPV vaccination uptake. 
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. 
  • Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study. 
  • Evaluating human papillomavirus vaccination programs. 
  • Evaluation of Women's Empowerment in a Community-Based Human Papillomavirus Self-Sampling Social Entrepreneurship Program (Hope Project) in Peru: A Mixed-Method Study. 
  • Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. 
  • Evolution of terminology for human-papillomavirus-infection-related vulvar squamous intraepithelial lesions. 
  • Examining Associations between Knowledge and Vaccine Uptake Using the Human Papillomavirus Knowledge Questionnaire (HPV-KQ). 
  • Expanding Indications for the Human Papillomavirus Vaccine: One Small Step for the Prevention of Head and Neck Cancer, but One Giant Leap Remains. 
  • Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. 
  • Extended Human Papillomavirus Genotyping to Predict Progression to High-Grade Cervical Precancer: A Prospective Cohort Study in the Southeastern United States. 
  • FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. 
  • Factors Associated With Human Papillomavirus Vaccine Series Completion Among Adolescents. 
  • Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer. 
  • Female perspectives on male involvement in a human-papillomavirus-based cervical cancer-screening program in western Kenya. 
  • Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. 
  • Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy. 
  • Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx. 
  • Genetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck. 
  • Genetic variants of a BH3-only pro-apoptotic gene, PUMA, and risk of HPV16-associated squamous cell carcinoma of the head and neck. 
  • Geographic Variation in Human Papillomavirus Vaccination Initiation and Completion Among Young Adults in the U.S. 
  • Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. 
  • HPV Vaccination Is Safe-You Don't Have to Whisper It. 
  • HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. 
  • HPV clearance and the neglected role of stochasticity. 
  • HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. 
  • HPV vaccines: now that they're here, how do we maximize their benefit? 
  • HPV-based cervical cancer screening in low-resource settings: Maximizing the efficiency of community-based strategies in rural Kenya. 
  • HPV16-associated squamous cell carcinoma of the tongue metastatic to the ciliary body, iris, and lacrimal gland. 
  • High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins. 
  • High-risk human papillomavirus 16/18 associated with improved survival in sinonasal squamous cell carcinoma. 
  • How Providing Cervical Cancer Screening Results via Cell Phone Affects Patient Follow-Up Rates in Western Kenya. 
  • Human Papillomavirus Awareness in Haiti: Preparing for a National HPV Vaccination Program. 
  • Human Papillomavirus Vaccination Status and Parental Endorsement Intentions among Undergraduate Student Nurses. 
  • Human Papillomavirus Vaccination and Trends in Cervical Cancer Incidence and Mortality in the US. 
  • Human Papillomavirus-Related Cancer Surveillance, Prevention, and Screening Among Transgender Men and Women: Neglected Populations at High Risk. 
  • Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy? 
  • Human papillomavirus in early laryngeal carcinoma. 
  • Human papillomavirus infection and anxiety: analyses in women with low-grade cervical cytological abnormalities unaware of their infection status. 
  • Human papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, Haiti. 
  • Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. 
  • Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. 
  • Human papillomavirus vaccination uptake among Native Hawaiian and Pacific Islander adults in the United States. 
  • Human papillomavirus vaccine uptake among teens before and during the COVID-19 pandemic in the United States. 
  • Immunity to commensal papillomaviruses protects against skin cancer. 
  • Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort. 
  • Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 
  • Impact of Patient Navigation Interventions on Timely Diagnostic Follow Up for Abnormal Cervical Screening. 
  • Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies. 
  • Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. 
  • Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma. 
  • Increased Rate of ASCUS Diagnosis With Concomitant Request for High-Risk Human Papillomavirus Reflex Testing May Be Due to Cognitive Bias. 
  • Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States. 
  • Influence of parent characteristics and disease outcome framing on HPV vaccine acceptability among rural, Southern women. 
  • Influence of smoking history on imaging characteristics among patients with human papillomavirus-positive oropharyngeal cancer: a blinded matched-pair analysis. 
  • Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. 
  • Interleukin-10 promoter variants predict HPV-positive tumors and survival of squamous cell carcinoma of the oropharynx. 
  • Invasive and in situ cervical cancer reported to the vaccine adverse event reporting system (VAERS). 
  • Keen on teen vaccines: improvement of adolescent vaccine coverage in rural North Carolina. 
  • Key stakeholder perspectives on challenges and opportunities for rural HPV vaccination in North and South Carolina. 
  • Knowledge about human papillomavirus among adolescents. 
  • Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. 
  • Male Circumcision Reduces Penile HPV Incidence and Persistence: A Randomized Controlled Trial in Kenya. 
  • Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. 
  • Medical students' knowledge of HPV, HPV vaccine, and HPV-associated head and neck cancer. 
  • Missed Opportunities for Human Papillomavirus Vaccine Initiation in an Insured Adolescent Female Population. 
  • Missed opportunities for adolescent vaccination, 2006-2011. 
  • Mobile Phone Ownership and Use Among Women Screening for Cervical Cancer in a Community-Based Setting in Western Kenya: Observational Study. 
  • Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual Revolution. 
  • Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx. 
  • Monitoring and ordering practices for human papillomavirus in cervical cytology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 5. 
  • Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. 
  • Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. 
  • Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program. 
  • Not just a woman's business! Understanding men and women's knowledge of HPV, the HPV vaccine, and HPV-associated cancers. 
  • Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: evaluation by differential polymerase chain reaction. 
  • PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer. 
  • Patient factors affecting successful linkage to treatment in a cervical cancer prevention program in Kenya: A prospective cohort study. 
  • Pediatricians are more supportive of the human papillomavirus vaccine than the general public. 
  • Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study. 
  • Perspectives of women participating in a cervical cancer screening campaign with community-based HPV self-sampling in rural western Kenya: a qualitative study. 
  • Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. 
  • Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology. 
  • Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. 
  • Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. 
  • Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy. 
  • Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. 
  • Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. 
  • Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma. 
  • Promoting Strategies to Increase HPV Vaccination in the Pediatric Primary Care Setting. 
  • Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. 
  • Provider response and follow-up to parental declination of HPV vaccination. 
  • Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. 
  • Quality of Physician Communication about HPV Vaccine-Letter. 
  • Racial and Ethnic Differences in Acceptability of Urine and Cervico-Vaginal Sample Self-Collection for HPV-Based Cervical Cancer Screening. 
  • Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. 
  • Rectovaginal examinations and human papillomavirus: can we decrease the risk of colorectal infection? 
  • Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). 
  • Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. 
  • Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans. 
  • Risk and outcomes for second primary human papillomavirus-related and -unrelated head and neck malignancy. 
  • Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers. 
  • Rural-Urban Disparities in HPV Vaccination Coverage Among Adolescents in the Central Part of the State of Illinois, USA. 
  • Safety and Acceptability of Thermal Ablation for Treatment of Human Papillomavirus Among Women Living With HIV in Western Kenya. 
  • Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. 
  • Scaling up cervical cancer prevention in Western Kenya: Treatment access following a community-based HPV testing approach. 
  • Self-efficacy and HPV Vaccine Attitudes Mediate the Relationship Between Social Norms and Intentions to Receive the HPV Vaccine Among College Students. 
  • Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. 
  • Sexual behavior, HPV knowledge, and association with head and neck cancer among a high-risk group. 
  • Skin infections in HIV-infected individuals in the era of HAART. 
  • Sociodemographic Factors Associated With Knowledge and Risk Perception of Human Papillomavirus and Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma Among a Predominantly Black Population. 
  • Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. 
  • Stage 1 small cell cancer of the vagina. 
  • Study protocol for a cluster-randomized trial to compare human papillomavirus based cervical cancer screening in community-health campaigns versus health facilities in western Kenya. 
  • Survival of human papillomavirus-associated cancers: Filling in the gaps. 
  • Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base. 
  • Swallowing Function Following Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Carcinoma: A 2-Year Follow-up. 
  • Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases. 
  • Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. 
  • Systems-level barriers to treatment in a cervical cancer prevention program in Kenya: Several observational studies. 
  • TGFβ1 Genetic Variants Predict Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy. 
  • Telomere length in peripheral blood lymphocytes contributes to the development of HPV-associated oropharyngeal carcinoma. 
  • Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans. 
  • Test Accuracy of Human Papillomavirus in Urine for Detection of Cervical Intraepithelial Neoplasia. 
  • The HPV vaccine: are dosing recommendations being followed? 
  • The LAST guidelines in clinical practice: implementing recommendations for p16 use. 
  • The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC. 
  • The association of oncogenic human papillomaviruses with urologic malignancy. The controversies and clinical implications. 
  • The current and future role of screening in the era of HPV vaccination. 
  • The economic impact of HPV vaccines: not just cervical cancer. 
  • The effectiveness of pay-it-forward in addressing HPV vaccine delay and increasing uptake among 15-18-year-old adolescent girls compared to user-paid vaccination: a study protocol for a two-arm randomized controlled trial in China. 
  • The impact of human papillomavirus vaccination on cervical cancer prevention efforts. 
  • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. 
  • The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. 
  • The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. 
  • The prevalence of cervical regulatory T cells in HPV-related cervical intraepithelial neoplasia (CIN) correlates inversely with spontaneous regression of CIN. 
  • The role of human papilloma virus infection in the etiology of oropharyngeal carcinoma. 
  • The value of follow-up FDG-PET/CT in the management and prognosis of patients with HPV-positive oropharyngeal squamous cell carcinoma. 
  • There's Much Yet to be Done: Diverse Perspectives on HPV Vaccination. 
  • Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females. 
  • Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. 
  • Trichodysplasia spinulosa--a newly described folliculocentric viral infection in an immunocompromised host. 
  • US physicians' intentions regarding impact of human papillomavirus vaccine on cervical cancer screening. 
  • Understanding of risk factors for the human papillomavirus (HPV) infection based on gender and race. 
  • Unique Primary Care Needs of Transgender and Gender Non-Binary People. 
  • Uptake and correlates of cervical cancer screening among women attending a community-based multi-disease health campaign in Kenya. 
  • Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco use. 
  • Vaginal Self-Sampling for Human Papillomavirus Infection as a Primary Cervical Cancer Screening Tool in a Haitian Population. 
  • Vitamin D status in patients with oropharyngeal cancer: Association with HPV status and prognosis. 
  • p53 codon 72 polymorphism associated with risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never-smokers. 
  • p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. 
• 

  Keywords of People

  • Cohen, Seth Morris, Professor of Head and Neck Surgery & Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology